Clinical outcomes after re-operative CABG remained constant during the period from 1985 to 2001 despite increasing age and comorbidities among patients.
Background: A meta-analysis was performed to identify significant differences in outcome between CABG with cardiopulmonary bypass (CPB) and CABG without CPB, "offpump" CABG.
Methods: 41 studies that provided 30 day mortality data on off-pump CABG compared to CABG using CPB were analyzed for differences in study design, pre-operative demographics, operative strategy, post-operative morbidity, and survival rates.
Results: In 8 of the 10 studies performed prior to 1996, off-pump CABG was associated with a significant 30 day survival rate disadvantage (odds ratio of survival 0.73; 95% CI 0.56 -0.94; p = 0.02). These 8 studies reported a higher percentage of females undergoing off-pump surgery compared to CABG with CPB . However, off-pump CABG was associated with significant improvements in both 30 day and 15 month average survival rates in the 31 studies performed after 1995, even when there were proportionately more females undergoing off pump surgery compared to CABG with CPB (30 day odds ratio of survival 1.56; 95% CI 1.33-1.84; p = 0.001; 15 month average follow-up odds ratio of survival 1.89, 95% CI 1.24-2.89, p=0.001). Furthermore, post-operative morbidity was significantly less in patients who underwent off-pump CABG versus CABG with CPB after 1995. Commercially available cardiac stabilization devices, which became available in 1996, were uniformly used in 30 of the 31 studies after 1995, but were not consistently employed in the 10 studies performed before 1996 (30/31 v. 0/10, p = 0.00001). These devices could be particularly important in the treatment of women, who have smaller diameter coronary vessels which are more technically challenging to bypass.
Conclusions:
Compared to CABG with CPB, off-pump CABG improves both short term and long term survival rates. These improvements in survival rates correlate with the use of commercially available stabilization devices, which may be particularly important in women. Furthermore, off-pump CABG is associated with markedly decreased post-operative morbidity. This suggests that off-pump CABG using commercially available stabilization devices should be the preferred method for surgical coronary revascularization. Background: Little is known about the impact of diabetes mellitus on outcomes during the first 12 months following CABG. Objectives: The purpose of our study was to examine the relationship between diabetes mellitus and clinical outcomes during the first 12 months following CABG. Methods: The ROSETTA-CABG Registry is a prospective multicenter study examining the use of functional testing after CABG. We examined 363 diabetic and non-diabetic patients enrolled in the registry at 16 clinical centers in 6 countries. Diabetes status was defined by medication use at discharge. Only patients undergoing a first successful isolated CABG in which all ischemic areas were thought to be revascularized were included. Results: Among the 363 patients, 34 (8.9%) were receiving insulin at discharge, 62 (16.2%) were receiving oral hypoglycemic agents, and 267 (69.5%) were not receiving insulin or oral hypoglycemic agents. The patients were predominantly elderly men (mean age 63.2 + 10.2, 81.0% male). The mean number of arteries bypassed was 3.6 + 1.3. Insulin-treated patients had a higher incidence of composite clinical events (unstable angina, myocardial infarction, death) compared with patients receiving oral hypoglycemic agents and non-diabetic patients (17.6% versus 3.2% and 6.1%, respectively, insulin vs non-insulin p=0.02). There was also a trend for insulin-treated patients to have a higher incidence of composite procedural events (cardiac catheterization, PCI, repeat CABG) compared with patients receiving oral hypoglycemic agents and non-diabetic patients (11.8% versus 4.9% and 3.8% respectively, insulin vs non-insulin p=0.07). After controlling for baseline clinical characteristics, insulin use at discharge had a persistent association with composite clinical events (OR=3.19, 95% CI=1.07-9.56, p=0.04).
Conclusions: During the 12-month period after a successful CABG, insulin-treated patients have a higher rate of adverse events compared with patients receiving oral hypoglycemic agents and non-diabetic patients. These results suggest that diabetic patients may benefit from more aggressive surveillance following CABG. 
